Authors:
End, DW
Smets, G
Todd, AV
Applegate, TL
Fuery, CJ
Angibaud, P
Venet, M
Sanz, G
Poignet, H
Skrzat, S
Devine, A
Wouters, W
Bowden, C
Citation: Dw. End et al., Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro, CANCER RES, 61(1), 2001, pp. 131-137
Authors:
Karp, JE
Lancet, JE
Kaufmann, SH
End, DW
Wright, JJ
Bol, K
Horak, I
Tidwell, ML
Liesveld, J
Kottke, TJ
Ange, D
Buddharaju, L
Gojo, I
Highsmith, WE
Belly, RT
Hohl, RJ
Rybak, ME
Thibault, A
Rosenblatt, J
Citation: Je. Karp et al., Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial, BLOOD, 97(11), 2001, pp. 3361-3369
Authors:
Zujewski, J
Horak, ID
Bol, CJ
Woestenborghs, R
Bowden, C
End, DW
Piotrovsky, VK
Chiao, J
Belly, RT
Todd, A
Kopp, WC
Kohler, DR
Chow, C
Noone, M
Hakim, FT
Larkin, G
Gress, RE
Nussenblatt, RB
Kremer, AB
Cowan, KH
Citation: J. Zujewski et al., Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer, J CL ONCOL, 18(4), 2000, pp. 927-941
Citation: Dw. End, Farnesyl protein transferase inhibitors and other therapies targeting the ras signal transduction pathway, INV NEW DR, 17(3), 1999, pp. 241-258